Drug intelligence / Profile preview

high-dose influenza vaccine

Development stage
Unknown
Lead developer
Sanofi Pasteur
Modality
Whole Inactivated Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
Administration
Intramuscular
01

Overview

High-dose influenza vaccine is an inactivated influenza vaccine formulation that contains four times the amount of hemagglutinin antigen per strain compared to standard-dose vaccines. The increased antigen content is designed to elicit a stronger immune response and provide better protection against seasonal influenza viruses, particularly in older adults whose immune systems may respond less robustly to standard vaccines. The most widely used product is Fluzone High-Dose (including trivalent and quadrivalent formulations), which is indicated for active immunization against disease caused by the included strains of influenza A subtypes and type B viruses. It is administered as a single intramuscular injection (0.7 mL) annually for persons 65 years of age and older. Clinical studies have shown that high-dose formulations are more effective than standard doses at preventing laboratory-confirmed flu and related complications in this population[1][2][3][4][5].

Brand names
Fluzone High-DoseFluzone High-Dose Quadrivalent
Other names
high dose influenza vaccinationHD-IIVHD-TIVhigh-dose flu shot
02

Targets

HA (Hemagglutinin)

Beyond the preview

Go deeper on high-dose influenza vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on high-dose influenza vaccine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call